Real-World Safety of Trastuzumab Deruxtecan in HER2-Positive Breast Cancer: A Single-Institutional Experience in Korea with Emphasis on ILD and HBV Reactivation

First Author / 第一作者

Hyelimg Kang

Institution / 單位

Dankook University Hospital, South Korea

Audio / 音訊檔

Author Group / 作者群

Hyelim Kang, M.D., M.S, Eui Tae Kim, M.D., Ph.D., Myeong Chul Jang, M.D., Ph.D., Junwon Min, M.D., Ph.D. *Corresponding author: Junwon Min, M.D., Ph.D (junwon77@naver.com)

Author Group Institution/ 作者群單位

Department of Surgery, Dankook University College of Medicine, Cheonan, Republic of Korea

Category / 主題分類

Clinical Research

Keyword / 關鍵字

Trastuzumab deruxtecan, HER2-positive breast cancer, Hepatitis B virus reactivation, Interstitial lung disease (ILD)/pneumonitis, Real-world data

Back to list